M Ogawara
21 Papers
190 Citations
M Ogawara is an academic researcher. The author has contributed to research in topics: Lung cancer & Etoposide. The author has an hindex of 10, co-authored 20 publications.
Chat about Author
Papers
Second primary tumours in more than 2-year disease-free survivors of small-cell lung cancer in Japan: the role of smoking cessation
Masaaki Kawahara,S Ushijima,T. Kamimori,Kodama N,M Ogawara,Kaoru Matsui,N Masuda,M Takada,T Sobue,Kiyoyuki Furuse +9 more
TL;DR: Patients with small-cell lung cancer who survive more than 2 years have a significantly increased risk of developing a second primary tumour and the cessation of cigarette smoking after successful therapy is associated with a significantly decreased risk of a secondPrimary tumour.
139
A Phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small cell lung cancer
Kiyoyuki Furuse,Kaoru Kubota,Masaaki Kawahara,M Ogawara,Etuo Kinuwaki,Masakichi Motomiya,Yutaka Nishiwaki,Hisanobu Niitani,Akira Sakuma +8 more
TL;DR: A weekly schedule of intravenous administration of 25 mg/m 2 /week of NVB was reasonable for maintenance of activity, and acceptable for toxicity in the chemotherapy of advanced NSCLC.
83
A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin.
Masahiro Fukuoka,Noriyuki Masuda,Kiyoyuki Furuse,S. Negoro,Minoru Takada,Kaoru Matsui,Nobuhide Takifuji,S. Kudoh,Masaaki Kawahara,M Ogawara +9 more
TL;DR: Analyses of prognostic factors showed that treatment with MVP, sex, and histologic classification (squamous cell carcinoma) were predictive of improved response and important factors for improved survival were the stage of disease, performance status,sex, weight loss before diagnosis, and hemoglobin concentration.
72
Phase II study of concurrent radiotherapy and chemotherapy for unresectable stage III non-small-cell lung cancer. Southern Osaka Lung Cancer Study Group.
Kiyoyuki Furuse,Kaoru Kubota,Masaaki Kawahara,Kodama N,M Ogawara,M. Akira,S Nakajima,Minoru Takada,Yoko Kusunoki,S. Negoro +9 more
TL;DR: In this article, the authors evaluated the response rate, toxicity, and 2-year survival rate of concurrent radiotherapy and chemotherapy for unresectable stage III non-small-cell lung cancer (NSCLC).
59
CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer.
Masahiro Fukuoka,N Masuda,S. Negoro,Kaoru Matsui,Takashi Yana,Shouji Kudoh,Yoko Kusunoki,M Takada,Masaaki Kawahara,M Ogawara,Kodama N,Kaoru Kubota,Kiyoyuki Furuse +12 more
TL;DR: RhG-CSF administration in support of CODE chemotherapy resulted in increased mean total received dose intensity for all drugs and a significant improvement in survival.
56